{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.04","upperLimit":"2.56","value":"1.15"},{"groupId":"OG001","lowerLimit":"5.74","upperLimit":"7.94","value":"6.84"},{"groupId":"OG002","lowerLimit":"4.30","upperLimit":"8.30","value":"6.30"},{"groupId":"OG003","lowerLimit":"0.923","upperLimit":"7.01","value":"3.97"},{"groupId":"OG004","lowerLimit":"0.515","upperLimit":"9.50","value":"6.33"},{"groupId":"OG005","lowerLimit":"0.146","upperLimit":"13.1","value":"6.43"},{"groupId":"OG006","lowerLimit":"6.43","upperLimit":"16.6","value":"7.96"},{"groupId":"OG007","lowerLimit":"0.0560","upperLimit":"19.6","value":"10.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"47"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"13"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.909","upperLimit":"11.1","value":"3.98"},{"groupId":"OG001","lowerLimit":"6.72","upperLimit":"17.1","value":"10.1"},{"groupId":"OG002","lowerLimit":"11.1","upperLimit":"21.4","value":"16.3"},{"groupId":"OG003","lowerLimit":"1.78","upperLimit":"19.2","value":"11.4"},{"groupId":"OG004","lowerLimit":"1.74","upperLimit":"28.7","value":"12.5"},{"groupId":"OG005","lowerLimit":"1.50","upperLimit":"33.0","value":"11.6"},{"groupId":"OG006","lowerLimit":"8.14","upperLimit":"28.8","value":"16.3"},{"groupId":"OG007","lowerLimit":"4.82","upperLimit":"25.0","value":"15.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.75","upperLimit":"2.75","value":"2.75"},{"groupId":"OG003","lowerLimit":"8.82","upperLimit":"8.82","value":"8.82"},{"groupId":"OG004","lowerLimit":"0.325","upperLimit":"10.6","value":"7.00"},{"groupId":"OG005","lowerLimit":"0.0759","upperLimit":"17.7","value":"6.58"},{"groupId":"OG006","lowerLimit":"0.661","upperLimit":"18.1","value":"9.39"},{"groupId":"OG007","lowerLimit":"0.248","upperLimit":"19.0","value":"12.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.860","upperLimit":"13.0","value":"3.71"},{"groupId":"OG001","lowerLimit":"7.11","upperLimit":"15.4","value":"9.58"},{"groupId":"OG002","lowerLimit":"12.9","upperLimit":"20.0","value":"16.5"},{"groupId":"OG003","lowerLimit":"1.27","upperLimit":"38.5","value":"13.4"},{"groupId":"OG004","lowerLimit":"2.07","upperLimit":"33.5","value":"14.9"},{"groupId":"OG005","lowerLimit":"0.269","upperLimit":"36.0","value":"14.3"},{"groupId":"OG006","lowerLimit":"8.47","upperLimit":"27.8","value":"14.7"},{"groupId":"OG007","lowerLimit":"6.18","upperLimit":"39.9","value":"18.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"66"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"SG3199: Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}],"units":"Participants"}],"title":"SG3199: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"69"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"13"}],"units":"Participants"}],"description":"Thalf of Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).\n\nResults for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.","dispersionType":"Full Range","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG004","title":"Parts 1 and 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG005","title":"Parts 1 and 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG006","title":"Part 1: 200 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG007","title":"Part 1: 200 μg/kg Q6W"}],"paramType":"MEDIAN","populationDescription":"Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)","title":"Terminal Half-life (Thalf) of ADCT-402","type":"SECONDARY","unitOfMeasure":"days"}